Experimental drug is helpful against c. diff, animal study finds

An experimental compound, which investigators say could be used as an alternative to antibiotics, has been shown to be effective in fighting Clostridium difficile in laboratory mice.

The compound mimics a natural cellular defense mechanism that neutralizes the toxins that cause c. difficile. The disease, which causes severe diarrhea, is one of the most common healthcare-acquired infections and can prove deadly in elderly nursing home residents.

In laboratory studies, conducted by investigators at University of California, Los Angeles, Case Western Reserve University, Tufts University and the Commonwealth Medical College and the University of Texas Medical Branch at Galveston, mice treated with the compound became less ill and were more likely to survive C. diff infection than untreated mice, according to the study.

"This may prove to be an alternative to antibiotics," study author Tor Savidge, M.D., told Reuters, adding that more study is needed.

The study was published in the journal Nature Medicine.

More in News

Experts tell lawmakers: Obama Medicare proposals would hurt long-term care — or maybe not

Experts tell lawmakers: Obama Medicare proposals would hurt ...

U.S. lawmakers heard mixed messages at a hearing Tuesday on how proposed Medicare cost-sharing reforms would impact long-term care. The House Ways and Means Subcommittee on Health focused in particular ...

Nursing home administrators can rise to 'unrealistic expectations' with disaster management, expert ...

One day after a powerful tornado destroyed a hospital and devastated an Oklahoma town, long-term care stakeholders gathered at a disaster preparedness conference organized by the Center for Preparedness Education, a joint endeavor of the Creighton University School of Medicine and the University of Nebraska ...

Long-term care physicians respond to report on antipsychotic over-prescribing

The top professional association of long-term care physicians and medical directors has reiterated its commitment to reducing the use of antipsychotics for dementia care. It did so Tuesday, in response to a recent report that criticized prescribing practices.